We’re off to the European Academy of Allergy and Clinical Immunology - EAACI Congress 2025 in Glasgow, UK! We look forward to presenting new clinical data on #FoodAllergy treatment and diagnosis, including data from year two of the EPITOPE Phase 3 extension study on the potential real-world effects of our investigational treatment option in peanut-allergic toddlers, as well as Phase 2 results from the APTITUDE study for diagnosis of non-IgE-mediated cow’s milk allergy in infants. We’re also hosting a scientific symposium on #PeanutAllergy where experts and community leaders will explore the allergist-patient relationship and share emerging insights from the field. Don’t miss out! Read the release for presentation details and visit our booth to learn more: https://bit.ly/44a5LCx #EAACI2025
DBV Technologies
Biotechnology Research
Châtillon, France 17,407 followers
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™
About us
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
- Website
-
http://www.dbv-technologies.com
External link for DBV Technologies
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Châtillon, France
- Type
- Public Company
- Specialties
- Allergy, Food and pediatric allergy, and Specific immunotherapy
Locations
-
Primary
Get directions
107, Avenue de la République
Châtillon, France 92320, FR
-
Get directions
10 Independence Blvd
Warren, New Jersey 07059, US
Employees at DBV Technologies
Updates
-
As Food Allergy Awareness Month comes to a close, we’re proud to stand with the food allergy community – advocating for greater awareness, advancing research, and supporting families and caregivers. At DBV Technologies, our commitment doesn’t end in May – we remain focused on delivering new solutions for those living with food allergies. Together, we’re building a future of greater understanding and hope. #FoodAllergyAwarenessMonth
-
-
At DBV Technologies, we’re pioneering a novel approach to #FoodAllergy treatment with our platform technology. By delivering tiny amounts of allergen through the skin, we aim to safely re-educate the immune system and help reduce allergic reactions. Learn more about our non-invasive approach and technology here: https://bit.ly/4fWxxFk
-
-
🤔 Myth or Fact? If a food doesn’t typically contain an allergen, or if the allergen is not listed on the label, it’s safe to eat. Myth! #FoodAllergens can appear in unexpected places. This #FoodAllergyAwarenessWeek, we’re raising awareness about the importance of reading food labels for those managing life with #FoodAllergies. Learn how to spot potential allergens and find out exactly what to look for on food labels with resources from FARE (Food Allergy Research & Education): https://bit.ly/44lXcFh #FAAW
-
This Food Allergy Awareness Week, we were featured on the Nasdaq Tower in Times Square. Seeing our mission lit up in the heart of New York City is a powerful reflection of our ongoing commitment to the #FoodAllergy community. As we continue working to improve the lives of the millions of children, families, and caregivers affected by food allergies, we’re honored to help raise awareness on this global stage. Learn more about us here: https://bit.ly/3S6OALw #FAAW
-
Last week, our team came together for another year at Allergy & Asthma Day on Capitol Hill (#AADCH) to champion the needs of those living with allergies, asthma and related conditions. As Allergy & Asthma Network celebrated its 40th anniversary, this year’s AADCH theme — 40 Years of Advocacy, Awareness, and Impact — highlighted the power of patient voices in shaping public health policy. Thank you for another successful and meaningful turnout on Capitol Hill! #FoodAllergyAwarenessWeek #FAAW
✅ That’s a wrap on #AADCH2025! Today, advocates from across the country came together on Capitol Hill to speak up for the 80+ million Americans living with asthma and allergies. We shared stories, pushed for policy change, and reminded Congress that every breath matters. Thank you to everyone who raised their voice. Let’s keep the momentum going — advocacy doesn’t end here. 💪💙 #Asthma #Allergy #Advocacy #Congress #BreatheBetter #Advocates #UseYourVoice #PBMReform
-
-
Did you know? More than 60% of food allergy reactions at school happen in preschools and child care facilities, putting our youngest students at the highest risk. During #FoodAllergyAwarenessWeek, staying informed is key to making a difference and creating safer environments. Join us in raising awareness and learn more about #FoodAllergies in early childhood from FARE (Food Allergy Research & Education): https://bit.ly/4ddA8uG #FAAW
-
-
🌟May is #FoodAllergyAwarenessMonth🌟At DBV Technologies, we remain steadfast in our commitment to improving the lives of children and families affected by food allergies. This month, we’re proud to spotlight the #FoodAllergy community and our advocacy partners who are driving awareness and making a real impact – thank you for your ongoing support and collaboration! Learn more from: Allergy & Asthma Network, Asthma and Allergy Foundation of America, FARE (Food Allergy Research & Education), FAACT, Food Allergy & Anaphylaxis Connection Team, and Food Allergy Canada
-
A #FoodAllergy diagnosis can be overwhelming for a child. Involving them early and clearly communicating what’s safe, what’s not, and how to stay protected is key to helping them navigate daily life and manage their food allergy with confidence. Explore more helpful tips from FARE on how to talk to your child about their food allergy: https://bit.ly/4ivhteP
-
-
We’re pleased to share new research published in Annals of Allergy, Asthma & Immunology from the EPITOPE Phase 3 study, highlighting our investigational treatment option after 12 months in children with #PeanutAllergy – including those with atopic comorbidities. Read the full manuscript to learn more: https://bit.ly/44cH9K0
-